.png){kind=icon}
.png){kind=icon}
Return
Dual-Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab
.png){kind=icon}
OA
AI
M
DOI：10.1155/dth/1532359.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Bullous pemphigoid (BP) is the commonest autoimmune subepidermal blistering disease. Refractory cases and patients with comorbidities limiting conventional immunosuppression remain difficult to treat. Dual-biologic therapy has emerged as a rescue strategy.
Keywords:
bullous pemphigoid
dual biologic
dupilumab
omalizumab
refractory
rituximab
Type 2 inflammation
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.4
Papers:
4.8K
Citations:
7.1K
Organization
Cited Papers